

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



The following tables provide guidance for COVID-19 vaccination schedules based on age and medical condition and vaccine composition.

Table 1. Immunization Schedule for Children 6 Months through 17 Years of Age*

Type	Recipient Age	Product [†]	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
			Doses	Interval Between Doses [‡]	Doses	Interval Between Doses
mRNA vaccine	6 months through 5 years [§]	MONOVALENT Moderna: Blue vial cap with magenta-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 4–8 weeks [¶]	Dose 1 to 2	At least 4 weeks
	6 through 11 years	MONOVALENT Moderna: Blue vial cap with purple-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 4–8 weeks [¶]	Dose 1 to 2	At least 4 weeks
		BIVALENT Moderna: Blue vial cap with gray-bordered label	Booster dose: Bivalent			
			Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)
	12 through 17 years	MONOVALENT Moderna: Red vial cap with blue-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 4–8 weeks [¶]	Dose 1 to 2	At least 4 weeks
		BIVALENT Moderna: Blue vial cap with gray-bordered label	Booster dose: Bivalent			
			Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)
	6 months through 4 years	MONOVALENT Pfizer-BioNTech: Maroon vial cap with maroon-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 3–8 weeks [¶]	Dose 1 to 2	At least 3 weeks
5 through 11 years	MONOVALENT Pfizer-BioNTech: Orange vial cap with orange-bordered label	Primary series: Monovalent				
		Dose 1 to 2	At least 3–8 weeks [¶]	Dose 1 to 2	At least 3 weeks	
	BIVALENT Pfizer-BioNTech: Orange vial cap with orange-bordered label	Booster dose: Bivalent				
		Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)	
12 years through 17 years	MONOVALENT Pfizer-BioNTech: Gray vial cap with gray-bordered label	Primary series: Monovalent				
		Dose 1 to 2	At least 3–8 weeks [¶]	Dose 1 to 2	At least 3 weeks	
	BIVALENT Pfizer-BioNTech: Gray vial cap with gray-bordered label	Booster dose: Bivalent				
		Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)	
Protein subunit vaccine	12 years and older	MONOVALENT Novavax	Primary series: Monovalent			
		mRNA (Moderna, Pfizer-BioNTech) should be used for the booster dose.	Booster dose: Bivalent			
			Dose 1 to 2	At least 3–8 weeks [¶]	Dose 1 to 2	At least 3 weeks
			Dose 2 to 3	At least 8 weeks (2 months)	Dose 2 to 3	At least 8 weeks (2 months)

* Guidance related to special situations when vaccinating children, such as those who have a birthday before completing the primary series or booster dose, see [Special Situations for COVID-19 Vaccination of Children and Adolescents](#)

[†] Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate monovalent COVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series. Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine can be administered for the bivalent booster dose, regardless of the primary series product.

[‡] Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

[§] Administer 1 Pfizer Bio-NTech bivalent booster dose to children age 5 years who have completed a primary series of Moderna COVID-19 vaccine.

[¶] An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. A shorter interval (4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2. Immunization Schedule for Persons 18 Years of Age

Type	Recipient Age	Product*	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
			Doses	Interval Between Doses [†]	Doses	Interval Between Doses
mRNA vaccine	18 years and older	MONOVALENT Moderna Red vial cap with a blue-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 4–8 weeks [‡]	Dose 1 to 2	At least 4 weeks
		BIVALENT Moderna Blue cap with gray-bordered label	Booster dose [§] : Bivalent			
			Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)
	18 years and older	MONOVALENT Pfizer-BioNTech Gray vial cap with gray-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 3–8 weeks [‡]	Dose 1 to 2	At least 3 weeks
BIVALENT Pfizer-BioNTech: Gray vial cap with gray-bordered label		Booster dose [§] : Bivalent				
		Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)	
Protein subunit vaccine	18 years and older	MONOVALENT Novavax	Primary series: Monovalent			
			Dose 1 to 2	At least 3–8 weeks [‡]	Dose 1 to 2	At least 3 weeks
		Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine should be used for the booster dose.	Booster dose [§] : Bivalent			
			Dose 2 to 3	At least 8 weeks (2 months)	Dose 2 to 3	At least 8 weeks (2 months)
Adenovirus vector vaccine	18 years and older	MONOVALENT Janssen	Janssen COVID-19 vaccine is authorized for use in certain limited situations due to safety considerations. [¶]			
		Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine should be used for the booster dose.	Booster dose [§] : Bivalent			
			Administer a single booster dose at least 8 weeks (2 months) after the previous dose.			

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate monovalent COVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series. Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine can be administered for the booster dose, regardless of the primary series product.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. A shorter interval (4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.

§ A single Novavax booster dose (instead of a bivalent mRNA booster dose) may be given to persons 18 years of age or older who have not received a previous booster dose in **limited situations**. These situations are 1. an mRNA vaccine is contraindicated, or not available or 2. the recipient is unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. Administer the booster dose at least 6 months after the last primary series dose.

¶ For guidance on use of Janssen vaccine and retrospective record review, scheduling and administration see [Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendix A](#)

CDC Resources

[CDC COVID-19 vaccine clinical training and materials](#)

[CDC Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#)

[CDC Vaccine administration clinical materials](#)

[CDC Vaccine Storage and Handling Toolkit](#)